The EIF4G3 Knockout AGS Polyclonal Cells are a heterogeneous population of AGS gastric adenocarcinoma cells with CRISPR/Cas9-mediated disruption of the EIF4G3 gene. This polyclonal knockout format provides a pooled loss-of-function model for studying EIF4G3’s role in translation initiation without the clonal selection bias inherent in single-cell-derived lines. The targeted disruption enables investigation of gene function in a mixed genetic background representative of physiological cell populations.
The AGS cell line originates from a human gastric adenocarcinoma and displays epithelial morphology, making it a standard model in gastric cancer research. These cells retain key oncogenic pathways and are suitable for studies of gastric epithelial barrier function, limited acid secretion, and tumor cell proliferation. AGS cells are amenable to CRISPR/Cas9 editing and exhibit active mTOR and MAPK signaling, providing a relevant context for translational control studies.
EIF4G3 acts as a scaffold in the eIF4F complex, bridging eIF4E (cap-binding protein), eIF4A (RNA helicase), and eIF3 to drive cap-dependent translation initiation. mTORC1 regulates EIF4G3 function by phosphorylating 4E-BP1, which releases eIF4E to bind EIF4G3; growth factor receptors (e.g., EGFR) signal via PI3K/AKT and MAPK to activate mTORC1. EIF4G3 also interacts with PABP and eIF4B. Downstream, it facilitates translation of mRNAs encoding MYC, cyclin D1, BCL2, and VEGF, thereby promoting cell proliferation and survival.
In AGS gastric cancer cells, EIF4G3 knockout is predicted to impair cap-dependent translation of oncogenic and stress-responsive mRNAs, attenuating the expression of proteins that drive tumor growth and survival. Given the active mTORC1 pathway in AGS, this model may reveal dependencies on the eIF4F complex for maintaining malignant phenotypes under nutrient stress or hypoxia. It offers a system to investigate how gastric cancer cells adapt to reduced translation capacity and to identify mRNAs whose translation is selectively affected.
Researchers can validate EIF4G3 disruption by western blotting and RT-qPCR, and assess functional consequences through polysome profiling, cap-binding assays, proliferation (MTT, BrdU), apoptosis (annexin V), and migration/invasion studies. Drug sensitivity tests with mTOR inhibitors or translation inhibitors can identify synthetic vulnerabilities. This polyclonal knockout tool is suited for drug target validation, screening for translation inhibitors, and exploring mTOR pathway crosstalk in gastric cancer biology. For additional information, please contact Ascent Research.
